is tirzepatide dangerous to take (Zepbound) for weight loss Unanticipated Adverse Events With Tirzepatide:

"We incorporate information about pregnancy into patient and healthcare provider advertisements for both products, along with other relevant safety information." (The company also states that it does not promote or recommend any off-label usage of its products.) Eli Lilly, which manufactures Mounjaro, tells BabyCenter that they do not promote or encourage the use of the drug outside of its FDA-approved indication for type 2 diabetes

Tirzepatide is a once-weekly injection that has been shown to help people lose up to 25% of their body weight in 28 weeks (average weight loss of 52 lb), while Semaglutide has been shown to help people lose up to 12.5% of their body weight

Whilst offering substantial metabolic benefits, regulatory authorities including the MHRA have identified acute pancreatitis as an uncommon potential adverse effect

For comparisons among multiple groups, the homogeneity of variance was first assessed